HK1039483A1 - Bicycle pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation is use thereof - Google Patents

Bicycle pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation is use thereof

Info

Publication number
HK1039483A1
HK1039483A1 HK01107828A HK01107828A HK1039483A1 HK 1039483 A1 HK1039483 A1 HK 1039483A1 HK 01107828 A HK01107828 A HK 01107828A HK 01107828 A HK01107828 A HK 01107828A HK 1039483 A1 HK1039483 A1 HK 1039483A1
Authority
HK
Hong Kong
Prior art keywords
dihydropyrimidines
pyrimidines
bicyclic
bicycle
inhibitors
Prior art date
Application number
HK01107828A
Other languages
English (en)
Inventor
Ellen Myra Dobrusin
James Marino Hamby
James Bernard Kramer
Mel Conrad Schroeder
Howard Daniel Hollis Showalter
Peter Toogood
Susanne A Trumpp-Kallmeyer
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26775058&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1039483(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HK1039483A1 publication Critical patent/HK1039483A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK01107828A 1998-05-26 2001-11-08 Bicycle pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation is use thereof HK1039483A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8670898P 1998-05-26 1998-05-26
US12615899P 1999-03-25 1999-03-25
PCT/US1999/010187 WO1999061444A2 (en) 1998-05-26 1999-05-10 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation

Publications (1)

Publication Number Publication Date
HK1039483A1 true HK1039483A1 (en) 2002-04-26

Family

ID=26775058

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01107828A HK1039483A1 (en) 1998-05-26 2001-11-08 Bicycle pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation is use thereof

Country Status (29)

Country Link
US (1) US7501425B1 (hu)
EP (1) EP1080092B1 (hu)
JP (1) JP2002516327A (hu)
KR (1) KR20010043829A (hu)
CN (1) CN1138778C (hu)
AP (1) AP2000001964A0 (hu)
AT (1) ATE402177T1 (hu)
AU (1) AU763839B2 (hu)
BG (1) BG104960A (hu)
BR (1) BR9911590A (hu)
CA (1) CA2329703C (hu)
DE (1) DE69939168D1 (hu)
EA (1) EA003640B1 (hu)
EE (1) EE200000706A (hu)
ES (1) ES2310039T3 (hu)
GE (1) GEP20033093B (hu)
HK (1) HK1039483A1 (hu)
HR (1) HRP20000799A2 (hu)
HU (1) HUP0102514A3 (hu)
ID (1) ID27589A (hu)
IL (1) IL139599A0 (hu)
IS (1) IS5687A (hu)
NO (1) NO20005928D0 (hu)
NZ (1) NZ508268A (hu)
PL (1) PL344248A1 (hu)
SK (1) SK17532000A3 (hu)
TR (1) TR200003429T2 (hu)
WO (1) WO1999061444A2 (hu)
YU (1) YU73300A (hu)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK17532000A3 (sk) 1998-05-26 2002-08-06 Warner-Lambert Company Prípadne substituované 3,4-dihydrogenované pyrimidíny, ich použitie a farmaceutické formulácie na ich báze
ES2228123T3 (es) * 1998-10-23 2005-04-01 F. Hoffmann-La Roche Ag Heterociclos de nitrogeno biciclicos.
BR0014973A (pt) * 1999-10-21 2002-07-16 Hoffmann La Roche Ag G Heterociclos de nitrogênio bicìclico de alquilamino substituìdo como inibidores de proteìna quinase p38
HUP0203564A3 (en) * 1999-10-21 2004-07-28 Hoffmann La Roche Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinease, process for their preparation and pharmaceutical compositions containing them
OA12316A (en) 2000-01-24 2006-05-15 Warner Lambert Co 3-Aminoquinazolin-2,4-dione antibacterial agents.
AR030044A1 (es) * 2000-01-25 2003-08-13 Warner Lambert Co Pirido (2,3-d ) pirimidin-2,7-diaminas inhibidores de quinasas
US7053070B2 (en) 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
AR030053A1 (es) * 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CZ20022929A3 (cs) * 2000-03-06 2003-02-12 Warner-Lambert Company 5-Alkylpyrido[2,3-d]pyrimidinové inhibitory tyrosinových kinas
US6506749B2 (en) 2000-08-31 2003-01-14 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (I)
BR0113628A (pt) * 2000-08-31 2003-07-01 Hoffmann La Roche 7-oxo-piridopirimidinas como inibidores de uma proliferação celular
EP1333833B1 (en) 2000-10-23 2011-08-24 GlaxoSmithKline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compound for the treatment of CSBP/p38 kinase mediated diseases
GB0029015D0 (en) 2000-11-28 2001-01-10 Univ London Medical device
ES2259079T3 (es) 2001-01-19 2006-09-16 Smithkline Beecham Corporation Inhibidores de la actividad cinasa del receptor tie2 para tratar enfermedades angiogenicas.
ATE305303T1 (de) 2001-02-12 2005-10-15 Hoffmann La Roche 6-substituierte pyridopyrimidine
US7105667B2 (en) 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
EP1395585B1 (en) 2001-05-30 2006-01-04 Warner-Lambert Company LLC Antibacterial agents
GEP20063909B (en) * 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
ES2291630T3 (es) 2002-04-19 2008-03-01 Smithkline Beecham Corporation Nuevos compuestos.
PA8577501A1 (es) * 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
RU2324695C2 (ru) 2002-08-06 2008-05-20 Ф.Хоффманн-Ля Рош Аг 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
US7112676B2 (en) * 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
TW200413381A (en) * 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
ATE433967T1 (de) * 2003-01-17 2009-07-15 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
CN100497339C (zh) 2003-04-10 2009-06-10 霍夫曼-拉罗奇有限公司 嘧啶并化合物
DE10325133A1 (de) * 2003-06-04 2004-12-23 Bayer Cropscience Ag Triazolopyrimidine
MXPA06001098A (es) 2003-07-29 2006-04-24 Irm Llc Compuestos y composiciones utiles como inhibidores de proteina cinasa.
ATE356124T1 (de) 2003-11-13 2007-03-15 Hoffmann La Roche Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7- one
WO2005118544A2 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
BRPI0514750A (pt) * 2004-08-31 2008-06-24 Hoffmann La Roche derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
CA2576818A1 (en) * 2004-08-31 2006-03-09 F. Hoffmann-La Roche Ag Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
JP5111113B2 (ja) 2004-12-13 2012-12-26 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
EP1868612A4 (en) 2005-03-25 2010-03-24 Glaxo Group Ltd NOVEL CONNECTIONS
EP1865959A2 (en) 2005-03-25 2007-12-19 Glaxo Group Limited Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
PE20061193A1 (es) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
DE602007001952D1 (de) 2006-01-31 2009-09-24 Hoffmann La Roche 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
PT2168966T (pt) * 2007-06-15 2017-01-02 Msd Kk Derivado de bicicloanilina
MX2010008269A (es) 2008-02-01 2011-02-21 Takeda Pharmaceutical Inhibidores de hsp90.
CA2745970A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
AU2009325400A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
CA2748181C (en) * 2009-01-06 2019-07-16 Nathanael S. Gray Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
AU2010218781A1 (en) * 2009-02-25 2011-07-28 Msd K.K. Pyrimidopyrimidoindazole derivative
SA111320200B1 (ar) * 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
PT2600719E (pt) * 2010-08-05 2014-12-22 Univ Temple 8 ¿ alquilo -2 - substituído 7 ¿ oxo ¿ 7,8 ¿ diidropirido [2,3 ¿ d] pirimidina ¿ 6 ¿ carbonitrilos e seus usos
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PL2699553T3 (pl) 2011-04-22 2024-03-25 Signal Pharmaceuticals, Llc Podstawione diaminokarboksyamido- i diaminokarbonitrylo-pirymidyny, ich kompozycje i sposoby leczenia nimi
IN2014CN02805A (hu) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
ES2625256T3 (es) 2011-10-14 2017-07-19 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIA
US9108951B2 (en) 2011-10-14 2015-08-18 Bristol-Myers Squibb Company Substituted 5,6,7,8-tetrahydro-1,6-naphthyridines as factor XIa inhibitors
CA2876689C (en) * 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
RU2679130C2 (ru) * 2012-07-11 2019-02-06 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
KR102143257B1 (ko) 2012-10-12 2020-08-10 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제의 결정질 형태
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
EP3943087A1 (en) 2013-03-15 2022-01-26 Celgene CAR LLC Heteroaryl compounds and uses thereof
MX2015011514A (es) 2013-03-15 2016-08-11 Celgene Avilomics Res Inc Compuestos de heteroarilo y sus usos.
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
RS56924B9 (sr) * 2013-04-19 2019-09-30 Incyte Holdings Corp Biciklični heterocikli kao fgfr inhibitori
US9783504B2 (en) 2013-07-09 2017-10-10 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
HUE039268T2 (hu) 2013-10-18 2018-12-28 Eisai R&D Man Co Ltd Pirimidin FGFR4 inhibitorok
HUE059037T2 (hu) 2013-10-25 2022-10-28 Blueprint Medicines Corp Fibroblaszt növekedési faktor receptor gátlók
CN106170290A (zh) 2013-12-20 2016-11-30 西格诺药品有限公司 取代的二氨基嘧啶基化合物、其组合物及其治疗方法
TWI688564B (zh) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物
NO2760821T3 (hu) 2014-01-31 2018-03-10
CN103880861B (zh) * 2014-02-21 2016-02-03 温州医科大学 一种作用于FGF受体的4,6-二甲基-噁唑并[5,4-d]嘧啶-5,7（4H,6H）-二酮衍生物
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX2017010673A (es) 2015-02-20 2018-03-21 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10562888B2 (en) 2015-04-14 2020-02-18 Eisai R&D Management Co., Ltd. Crystalline FGFR4 inhibitor compound and uses thereof
WO2017196854A1 (en) 2016-05-10 2017-11-16 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
CN107459519A (zh) * 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
CN110225914A (zh) 2016-07-05 2019-09-10 布罗德研究所股份有限公司 双环脲激酶抑制剂及其用途
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
RU2019129727A (ru) 2017-02-28 2021-03-30 Зэ Дженерал Хоспитал Корпорэйшн Применения пиримидопиримидинонов в качестве ингибиторов sik
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3788047A2 (en) 2018-05-04 2021-03-10 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022004513A (es) 2019-10-14 2022-07-19 Incyte Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CR20220285A (es) 2019-12-04 2022-10-27 Incyte Corp Derivados de un inhibidor de fgfr
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
EP4175719A1 (en) 2020-07-02 2023-05-10 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949466A (en) 1958-03-04 1960-08-16 Parke Davis & Co Pyrimidine compounds and means of producing the same
ES338687A1 (es) 1966-04-06 1968-04-01 Monsanto Co Procedimiento para obtener composiciones de fluidos funcio-nales.
US3912723A (en) 1971-03-29 1975-10-14 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
FI66866C (fi) 1979-06-14 1984-12-10 Wellcome Found Foerfarande foer framstaellning av antiproliferativa 2,4-diamino-6-(dialkoxibensyl)pyrido(2,3-d)pyrimidiner
US4425346A (en) 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
JPS60226882A (ja) 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
EP0278686A1 (en) * 1987-02-07 1988-08-17 The Wellcome Foundation Limited Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof
WO1992020642A1 (en) * 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
AU701127B2 (en) 1994-10-27 1999-01-21 Merck & Co., Inc. Muscarine antagonists
PT790997E (pt) * 1994-11-14 2000-06-30 Warner Lambert Co 6-aril pirido¬2,3-d|pirimidinas e naftiridinas para inibir a proliferacao celular mediada pela quinase da tirosina proteica
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
CZ295468B6 (cs) 1996-04-12 2005-08-17 Warner-Lambert Company Polycyklické sloučeniny
KR20000070751A (ko) 1997-02-05 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
JP4965021B2 (ja) 1997-08-20 2012-07-04 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー プロテインチロシンキナーゼおよび細胞周期キナーゼ仲介細胞増殖を阻害するためのナフチリジノン
JP4038624B2 (ja) 1997-11-29 2008-01-30 日本農薬株式会社 縮合複素環誘導体及びその中間体並びに有害生物防除剤
SK17532000A3 (sk) 1998-05-26 2002-08-06 Warner-Lambert Company Prípadne substituované 3,4-dihydrogenované pyrimidíny, ich použitie a farmaceutické formulácie na ich báze
ES2228123T3 (es) 1998-10-23 2005-04-01 F. Hoffmann-La Roche Ag Heterociclos de nitrogeno biciclicos.
BR0014973A (pt) 1999-10-21 2002-07-16 Hoffmann La Roche Ag G Heterociclos de nitrogênio bicìclico de alquilamino substituìdo como inibidores de proteìna quinase p38
HUP0203564A3 (en) 1999-10-21 2004-07-28 Hoffmann La Roche Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinease, process for their preparation and pharmaceutical compositions containing them
AR030053A1 (es) 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas

Also Published As

Publication number Publication date
AP2000001964A0 (en) 2000-12-31
ES2310039T3 (es) 2008-12-16
EE200000706A (et) 2002-06-17
JP2002516327A (ja) 2002-06-04
AU763839B2 (en) 2003-07-31
BG104960A (en) 2001-10-31
SK17532000A3 (sk) 2002-08-06
EP1080092B1 (en) 2008-07-23
EA003640B1 (ru) 2003-08-28
CA2329703C (en) 2005-12-20
DE69939168D1 (de) 2008-09-04
WO1999061444A2 (en) 1999-12-02
HUP0102514A2 (hu) 2001-11-28
TR200003429T2 (tr) 2001-07-23
ATE402177T1 (de) 2008-08-15
KR20010043829A (ko) 2001-05-25
GEP20033093B (en) 2003-10-27
HUP0102514A3 (en) 2002-03-28
IS5687A (is) 2000-10-27
EP1080092A2 (en) 2001-03-07
HRP20000799A2 (en) 2001-06-30
US7501425B1 (en) 2009-03-10
CA2329703A1 (en) 1999-12-02
IL139599A0 (en) 2002-02-10
AU4073499A (en) 1999-12-13
NO20005928L (no) 2000-11-23
NO20005928D0 (no) 2000-11-23
ID27589A (id) 2001-04-12
BR9911590A (pt) 2001-02-13
WO1999061444A3 (en) 2000-02-03
NZ508268A (en) 2004-02-27
EA200001171A1 (ru) 2001-06-25
PL344248A1 (en) 2001-10-22
YU73300A (sh) 2003-08-29
CN1302301A (zh) 2001-07-04
CN1138778C (zh) 2004-02-18

Similar Documents

Publication Publication Date Title
HK1039483A1 (en) Bicycle pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation is use thereof
HU0003386D0 (en) Use of crf antagonists
EP1018987A4 (en) NEO-CARTILAGE AND ITS METHODS OF USE
HK1036801A1 (en) Pyrrolo(2,3-d)pyrimidine compounds, composition and use there of
EG24027A (en) Pyrrolotriazine inhibitors of kinases
SI1475377T1 (sl) Indolni derivati in njihova uporaba kot inhibitorji fosfodiesteraze 4
IL130900A0 (en) Atropisomers of 3-aryl-4(3H)- quinazolinones and their use as ampa-receptor antagonsts
IL130181A0 (en) Substituted pyrimidone and pyridone compounds and methods of use
HK1068874A1 (en) Heterocyclic compounds and methods of use
PL331221A1 (en) Heteroaromatic bicyclic compounds as inhibitors of propteinous tyrosine kinase
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
PL333505A1 (en) Benzamido-aldehydes and their application as inhibitors of cysteinic proteases
PL337645A1 (en) Novel amidine derivatives and their application as thrombosin inhibitors
HU9800112D0 (en) Biphenyl-sulfonyl-substituted heterocyclic compounds of fife-membered ring, their production and use
AU3786299A (en) Novel serotonin-like 9-substituted hypoxanthine and methods of use
PL325122A1 (en) Bicyclic derivatives of 4-aralkylamino pyrididine as inhibitors of thyrosinic kinase
MXPA02000779A (es) Factor de activacion de la citocina altamente purificada y metodos de uso.
PL361733A1 (en) Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
AU2517399A (en) Utilization of substituted sulfonamides as antiviral agents and novel substances
IL130180A0 (en) Substituted pyrimidine compounds and their use
AU1522400A (en) Substituted pyrimidine compositions and methods of use
HK1066804A1 (en) Derivatives of indole and their use as phosphodiesterase 4 inhibitors
EP1137412A4 (en) SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUNDS AND THEIR THERAPEUTIC USE
PL339493A1 (en) Bis-ethers of 1-oxa, aza and thinaphtalen-2-ones as phospholamane inhibitors
GB9600559D0 (en) Use of chemokines

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080510